Gastroenterologists often face a discrepancy between clinical indices and how patients perceive their illness. Specifically, tools like the IBD disease severity index (IBD-DSI) help clinicians quantify long-term severity. However, aligning these objective measures with the patient experience remains a challenge in clinical practice. A recent multicentre trial investigated this by correlating the physician-led IBD-DSI with a patient-completed disease severity score (PCDSS).

Researchers involved 164 patients in the study, comparing clinical scores with self-reported assessments. Notably, the study found a moderate positive correlation between the IBD-DSI and the patient-reported scores. Despite this link, a significant gap exists. On average, patients reported higher severity than physicians, resulting in a mean excess severity score (ESS) of 29.0. Furthermore, these discrepancies were most prominent when clinical severity was rated as low by the physician. Consequently, physicians must recognize that patients may feel a higher burden even during periods of clinical stability.

Clinical Insights into the IBD Disease Severity Index

The study also analyzed factors that might explain this divergence in perception. Interestingly, surgical history played a major role. Patients with a history of colectomy or any bowel-related surgery typically reported a higher ESS. Additionally, the extent of disease in ulcerative colitis was significantly associated with a greater gap between patient and physician scores. Conversely, the use of 5-aminosalicylic acid (5-ASA) was negatively associated with the excess score. This suggests that certain treatments or disease milestones significantly shape how a patient perceives their cumulative disease burden.

Interestingly, psychological measures did not significantly moderate the correlation between the two indices. While there were non-significant trends for pain catastrophizing, variables like neuroticism and coping styles did not show a statistical link to the excess severity score. Therefore, the mismatch between patient and doctor appears more tied to clinical characteristics and treatment history rather than personality traits. Ultimately, incorporating both the IBD disease severity index and patient-reported outcomes provides a more holistic view of the disease journey.

Frequently Asked Questions

How does the IBD disease severity index help in patient management?

The IBD-DSI allows clinicians to describe cumulative disease severity over time. By comparing this with patient scores, doctors can identify gaps where the patient's perceived burden exceeds clinical findings, allowing for more personalized care.

Why do patients often report higher severity than clinical indices?

This discrepancy, known as the excess severity score, is often linked to clinical milestones like past surgeries or disease extent. Patients may prioritize different factors, such as the long-term impact on daily life, compared to the objective markers used in clinical tools.

Did mental health factors affect the correlation in this study?

The study found that psychological variables, including anxiety and neuroticism, did not significantly moderate the correlation between physician and patient scores. Instead, clinical factors like prior surgery were the primary drivers of the discrepancy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

McCombie AM et al. Correlation between patient-determined inflammatory bowel disease severity and the inflammatory bowel disease severity index. N Z Med J. 2026 Mar 13. doi: 10.26635/6965.7229. PMID: 41818761.

Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205-217.

Vind I, et al. Patient-reported outcomes in inflammatory bowel disease. World J Gastroenterol. 2016;22(1):1-15.